Biotech Values

[DewDiligence]

AYLA IPOs 4.22M* shares @$15.00:

https://www.globenewswire.com/news-release/2020/05/07/2030078/0/en/Ayala-Pharmaceuticals-Announces-Pricing-of-Initial-Public-Offering.html

https://www.sec.gov/Archives/edgar/data/1797336/000119312520065057/d846749ds1.htm#rom846749_10

[Ayala pharmaceuticals is] a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations.

Our differentiated development approach is predicated on identifying and addressing tumorigenic drivers of cancer, through a combination of our bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations.

…Our lead product candidate, AL101, is being developed as a potent, selective, injectable small molecule gamma secretase inhibitor, or GSI. We obtained an exclusive, worldwide license to develop and commercialize AL101 from Bristol-Myers Squibb Company…in November 2017. BMS evaluated AL101 in three Phase 1 studies in more than 200 subjects with various cancers who had not been prospectively characterized for Notch activation, and to whom we refer to as unselected subjects. While these Phase 1 studies did not report statistically significant overall results, clinical activity was observed across these studies in cancers in which Notch has been implicated as a tumorigenic driver.

.We are currently evaluating AL101 as a monotherapy in an open-label Phase 2 clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma, or R/M ACC, for patients bearing Notch-activating mutations.

The company was incorporated in 2017 and is headquartered in Rehovot, Israel.

*Assuming exercise of underwriter’s option.